Association Between Early Methadone Dose Titration and Treatment Discontinuation and Opioid Toxi

09 Apr 20264 min read0 viewsJournal Feed

GIST

by Ria Garg, Jin Luo, Nikki Bozinoff, Beth Sproule, Tony Antoniou, Jennifer Wyman, Pamela Leece, Charlotte Munro, Jes Besharh, Tara Gomes Background Clinical guidance in Canada and the United States recommends faster methadone dose titration for individuals using fentanyl. An initial dose increase is recommended between days 4 and 6, but the impact on patient outcomes remains unclear, particularly when provided in an outpatient setting.

Therefore, we evaluated the association between early methadone dose titration (i.e., within treatment days 4–6) and treatment discontinuation and opioid toxicity. Methods and findings We conducted a retrospective propensity-score weighted cohort study of Ontario residents who initiated methadone in an outpatient setting between January 2017 and December 2022.

Exposure was defined as provision of a dose titration between treatment days 4–6, with the index date defined as the first date of dose increase. For unexposed individuals, the index date was randomly assigned and followed the same distribution as those exposed.

Individuals were followed for up to 181 days following index date for study outcomes.

Clinical Editorial

Rationale and scope of the investigation

The study examines whether introducing an initial methadone dose increase between days 4 and 6 after treatment initiation influences subsequent treatment continuity and risk of opioid toxicity in outpatient settings.
It situates its question within clinical guidance in North America that endorses relatively rapid dose escalation for individuals with fentanyl exposure, and aims to clarify outcomes in a real-world, outpatient Ontario population.

Design, population, and exposure definition

Design: Retrospective cohort using propensity-score weighting and Cox proportional hazards analysis.
Population: Ontario residents initiating outpatient methadone treatment between January 2017 and December 2022.
Exposure: Provision of a methadone dose titration during treatment days 4–6, with the index date set to the first dose increase.
Comparator: Unexposed individuals had a randomly assigned index date mirroring the exposed group’s distribution.
Follow-up: Up to 181 days from the index date for study outcomes.
Primary outcomes: Methadone discontinuation and opioid toxicity, assessed with an intention-to-treat approach.
Secondary outcomes: Toxicity arising from non-methadone opioids while on treatment.

Analytical approach and variables

Confounding control: A propensity-score model estimated the probability of dose titration based on baseline demographics and clinical characteristics (e.g., comorbidities, past medication use).
Effect estimation: Propensity-score weighted Cox models quantified associations between early titration and outcomes.
Sample size and key characteristics: Among 13,560 incident methadone recipients, about 61.4% (n = 8,322) received early dose titration; mean age 36.5 years; roughly one-third female.

Major signals and outcome pattern

Treatment retention: Early dose titration was associated with a lower weighted hazard of discontinuation, strongest in the first week (wHR 0.55; 95% CI 0.51–0.60), with the effect attenuating over time.
Opioid toxicity on treatment: The weighted rate of opioid toxicity favored the early-titration group (10.1 vs 12.3 per 100 person-years; wHR 0.82; 95% CI 0.69–0.97).
Specificity to methadone-related toxicity: No excess risk observed with early titration; methadone-related toxicity remained low and was similar between groups (2.02 vs 2.65 per 100 person-years; wHR 0.80; 95% CI 0.46–1.41).
Non-methadone opioid toxicity: Most toxicities were attributed to non-methadone opioids with comparable rates between groups (3.89 vs 4.06 per 100 person-years; wHR 1.00; 95% CI 0.70–1.44).

Context and interpretation

The analysis suggests that initiating early dose increases within days 4–6 may contribute to better retention in methadone treatment and a modest reduction in opioid toxicity risk, without increasing methadone-specific toxicity while on treatment.
The observed benefit on discontinuation was most pronounced in the immediate post-index period, with diminishing effects over time.
The study design relies on observational data and employs propensity weighting to address confounding, but residual confounding remains possible due to unmeasured or time-varying factors.

Limitations and uncertainty

The main limitation is the absence of data on drug use history and time-varying clinical factors that could influence both the likelihood of dose titration and outcomes, introducing potential residual confounding.
Information gaps preclude definitive causal inference; associations observed do not establish causation.
The study focused on an Ontario outpatient population, which may limit generalizability to other settings or health systems.

Operational implications and future questions

The findings align with guidelines favoring timely dose titration and highlight potential benefits for retention and safety in the context of fentanyl exposure.